TP53 and malignant colon neoplasm: A recent study has shown that the impaired sensitivity of mutant p53-harboring HT29 colon cancer cells to oxaliplatin is significantly influenced by the dysregulated phosphorylation of the N- and C-terminus serine residues of the mutant p53 protein [65].